A critical gap is the absence and unavailability of a suitable chemo-prophylactic drug or formulation in India or globally that can help to bring down the transmission rates thereby helping to make the transition from high API to lower degrees. The prophylactic formulations currently available for malaria suffer from major handicaps like being contraindicated for pregnant and feeding women, children and people with certain genetic conditions. These medications also do not act for enough time frame to encourage wide adoption by population at risk. Malaria eradication necessitates new tools to fight the evolving and complex Plasmodium pathogens. Eliminating parasites in the human liver (host) prevents disease progression in the individual and eliminates transmission, as parasites never reach the blood stage. Despite imperfections in the evaluation model at the liver stages, hepatic targeted prophylactic drugs can play the game changer.